<DOC>
	<DOCNO>NCT00688753</DOCNO>
	<brief_summary>To evaluate preliminary efficacy safety RAD001 monotherapy first-line treatment patient metastatic papillary carcinoma kidney .</brief_summary>
	<brief_title>RAPTOR : RAD001 Monotherapy Treatment Advanced Papillary Renal Cell Tumors Program Europe</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . ≥ 18 year old . 2 . Patients metastatic papillary renal cell carcinoma , type I II . 3 . Patients least one measurable lesion . 4 . Patients ECOG Performance Status ≤1 . 5 . Adequate bone marrow function . 6 . Adequate liver function . 7 . Adequate renal function . 8 . Adequate lipid profile . Exclusion criterion : 1 . Patients radiation therapy within 28 day prior start study . 2 . Patients receive prior systemic treatment metastatic RCC . 3 . Patients receive prior therapy VEGF pathway inhibitor . 4 . Patients previously receive systemic mTOR inhibitor . 5 . Patients know hypersensitivity everolimus rapamycins excipients . 6 . Patients uncontrolled central nervous system ( CNS ) metastases . 7 . Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent . 8 . Patients known history HIV seropositivity . 9 . Patients autoimmune hepatitis . 10 . Patients active , bleeding diathesis . 11 . Patients severe and/or uncontrolled medical condition condition could affect participation study . 12 . Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer carcinoma situ uterine cervix . 13 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . 14 . Patients use investigational agent receive investigational drug ≤ 4 week prior study treatment start . 15 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>non clear cell carcinoma</keyword>
	<keyword>papillary cell renal carcinoma</keyword>
	<keyword>adult</keyword>
	<keyword>everolimus</keyword>
</DOC>